POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF TUMOR SHRINKAGE BY AXITINIB IN PATIENTS WITH RENAL CELL CARCINOMA.

被引：0
|
作者：
Chen, Y. [1 ]
Houk, B. A. [1 ]
Ruiz, A. [1 ]
Bair, A. A. [1 ]
Pithavala, Y. K. [1 ]
机构：
[1] Pfizer, San Diego, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [31] Axitinib in metastatic renal cell carcinoma
    Albiges, Laurence
    Gizzi, Marco
    Carton, Edith
    Escudier, Bernard
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (05) : 499 - 507
  • [32] Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma.
    Atkins, Michael B.
    Bhatt, Rupal Satish
    Voss, Martin Henner
    Rini, Brian I.
    Jonasch, Eric
    Plimack, Elizabeth R.
    Alter, Robert
    Barger, Rachel
    Wilson, Dawn
    McClure, Ty
    Kumar, Ravi
    Attie, Kenneth M.
    Sherman, Matthew L.
    Pandya, Shuchi Sumant
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Dose adjustment of axitinib based on AUC in sunitinib-pretreated metastatic renal cell carcinoma.
    Miura, Yuji
    Imamura, Chiyo K.
    Uchino, Keita
    Kishida, Takeshi
    Matsubara, Nobuaki
    Shinojima, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [34] Population pharmacokinetic modeling of avelumab to support flat dosing in patients with locally advanced or metastatic urothelial carcinoma.
    Li, Jerry
    Bello, Carlo
    Khandelwal, Akash
    Vugmeyster, Yulia
    Nickens, Dana
    Ruiz-Garcia, Ana
    Lin, Swan
    CANCER RESEARCH, 2021, 81 (13)
  • [35] Population Pharmacokinetic and Pharmacodynamic Modeling of Pegvisomant in Asian and Western Acromegaly Patients
    Muto, Chieko
    Chiba, Koji
    Suwa, Toshio
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12): : 1628 - 1643
  • [36] Population Pharmacokinetic-Pharmacodynamic Modeling of Intrathecal Ropivacaine in Orthopedic Patients
    Gaudreault, Francois
    Drolet, Pierre
    Fallaha, Michel
    Varin, France
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S95 - S95
  • [37] Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies
    Shi, Jack G.
    Bowman, Kevin J.
    Chen, Xuejun
    Maleski, Janet
    Leopold, Lance
    Yeleswaram, Swamy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (06): : 720 - 729
  • [38] Prognostic value of hemoglobin level increase during axitinib treatment for metastatic renal cell carcinoma.
    Johnson, Alison Claire
    Matias, Margarida
    Coquan, Elodie
    Brachet, Pierre-Emmanuel
    Dugue, Audrey Emmanuelle
    Molinier, Alicia
    Mourey, Loic
    Boyle, Helen Jane
    Laguerre, Brigitte
    Helissey, Carole
    Escudier, Bernard J.
    Joly, Florence
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [39] Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach
    Houk, B. E.
    Bello, C. L.
    Michaelson, M. D.
    Bukowski, R. M.
    Redman, B. G.
    Hudes, G. R.
    Wilding, G.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] A prospective phase II trial of gemcitabine plus axitinib in patients with sarcomatoid type renal carcinoma.
    Park, Inkeun
    Lee, Hyo Jin
    Bae, Woo Kyun
    Yoon, Shinkyo
    Lee, Jae-Lyun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345